NV PillBot Series A-2 SEC Review: The $13.36 Million Raise Has a Much Bigger Fee Question Than the Headline Shows
INDEPENDENT VERDICT
NV PillBot Series A-2 Partners LLC has a strong public identity trail but also contains one of the more important related-party disclosures in this group of new Form D filings. The Delaware vehicle filed its initial Form D on October 5, 2026 after a September 30 first sale and reported the entire $13,359,060 offering sold to 49 investors. Neman Ventures LLC is identified directly on the filing as promoter and general partner, and Neman Ventures is now an SEC-registered investment adviser under SEC file 801-136912 and CRD 330770. The broader PillBot connection can also be independently supported: Neman Ventures publicly identifies Endiatx among its investments, and an earlier NV PillBot Series A Partners vehicle appears in Neman Ventures' Form ADV private-fund disclosures. The strongest risk, however, is hidden deeper in Item 16 of the new filing: $1,935,359 of offering proceeds is reported as used or proposed to be used for payments to related persons, equivalent to roughly 14.5% of the entire offering.
$1.935 MILLION OF A $13.359 MILLION FUND IS A MATERIAL RELATED-PARTY NUMBER
The most important disclosure in this review is not the number of investors. It is the use of proceeds.
The Form D reports $1,935,359 in gross proceeds as being used or proposed to be used for payments to persons required to be identified as executive officers, directors or promoters. Neman Ventures LLC is the only related person identified in Item 3 and is described as the general partner.
The issuer then provides an unusually specific explanation: $967,679.50 is a one-time payment covering the first five years, while another $967,679.50 is to remain in escrow for years six through ten.
That total represents approximately 14.5% of the $13.359 million offering.
The filing does not label the amount as a sales commission or finder's fee—in fact, both those categories are reported as $0. It should therefore not be described casually as a placement commission. But regardless of the precise contractual label, it is a substantial economic payment to a related party and investors should understand exactly what services it covers.
For a concentrated venture vehicle, investors should ask whether this payment represents management fees, administrative compensation, carried economics or some combination; whether the second five-year amount becomes payable automatically; what happens to escrowed funds if the underlying investment exits before year six; and whether additional expenses or performance allocations can be charged on top of the $1.935 million.
THE PREVIOUS PILLBOT FUND USED A VERY SIMILAR TEN-YEAR PAYMENT STRUCTURE
This is not the first Neman PillBot vehicle.
NV PillBot Series A Partners, LLC filed an earlier Form D in December 2024. Its filing ultimately reported $13,560,500 sold to 70 investors and disclosed approximately $2,592,100 of proceeds for payments to related persons. That earlier filing described a remarkably similar arrangement: approximately $1.296 million paid upfront for five years and an equal amount placed in escrow for years six through ten.
That repetition is useful because it suggests the new Series A-2 economics are not a random one-off disclosure. They appear consistent with an established Neman SPV compensation structure.
But it also makes fee diligence more important.
The original PillBot fund's related-person amount represented roughly 19% of its reported raise, while Series A-2 reports approximately 14.5%. An investor should therefore evaluate returns on a net-of-all-SPV-economics basis, not simply compare the price paid for exposure to Endiatx with the headline company valuation.
NEMAN VENTURES NOW HAS A MUCH STRONGER REGULATORY FOOTPRINT
There is a significant positive regulatory development compared with many small SPV managers.
Neman Ventures LLC is currently registered with the SEC as an investment adviser. IAPD identifies the firm under CRD 330770 and SEC file 801-136912, with SEC registration effective August 5, 2026. Before that registration, the firm had operated as an exempt reporting adviser.
Its July 2026 Form ADV reported approximately $853.7 million in regulatory assets under management, substantially all associated with pooled investment vehicles.
More importantly for this review, the earlier NV PillBot Series A Partners vehicle appears in Neman's Form ADV Schedule D. That disclosure identifies Carta Investor Services as administrator, Cherry Bekaert as auditor and Bank of America as custodian, and states that the earlier fund receives an annual audit.
Those are meaningful institutional verification points.
However, investors should not automatically transfer every service-provider relationship from the original PillBot fund to Series A-2. The new vehicle was formed and sold after the July 2026 ADV data reviewed here, and a clean Series A-2-specific Schedule D entry has not yet been independently confirmed.
The correct conclusion is therefore that Neman Ventures itself is now a verified SEC-registered adviser and the predecessor PillBot fund has identifiable institutional service providers, not that every one of those providers has already been independently verified for Series A-2.
THE FUND NAME POINTS STRONGLY TOWARD ENDIATX — BUT FORM D DOES NOT IDENTIFY THE PORTFOLIO COMPANY
The name "PillBot" strongly points toward Endiatx.
Neman Ventures publicly lists Endiatx among its portfolio companies, and Neman's own performance material states that it led Endiatx's Series A and that Shane Neman joined the company's board. Public financing databases likewise identify Neman Ventures or Shane Neman among Endiatx investors.
This creates a coherent connection between the investment manager, the predecessor PillBot vehicle and the new Series A-2 fund.
But there is still an important evidentiary boundary.
The October 2026 Form D itself does not state "Endiatx" and does not identify the security being purchased. FilingDossier therefore would not claim solely from the Form D that every dollar in Series A-2 has already been invested directly into Endiatx Series A-2 securities.
An investor should obtain the SPV subscription agreement and underlying purchase documentation showing the precise Endiatx security class, share price, financing round, ownership rights and any markup between the SPV's purchase price and the investor's effective entry price.
PILLBOT IS STILL AN INVESTIGATIONAL DEVICE — NOT AN FDA-APPROVED PRODUCT
This is the largest operating-company risk and should not be buried beneath the excitement around the technology.
Endiatx's own current website explicitly states that PillBot, PillVue and its other robotic technologies are investigational devices under development and have not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory body. They are not currently available for commercial sale or clinical use.
That matters because Endiatx had previously discussed ambitious development timelines around regulatory clearance and commercialization.
Investment marketing around medical robotics can easily blur the distinction between a successful prototype, human testing, an FDA submission and actual FDA authorization. Those are completely different milestones.
Until regulatory authorization is actually obtained, investors face the possibility that additional trials will be required, regulatory review will take longer than expected, device specifications will change, reimbursement will prove difficult or the product will never achieve commercial clearance.
A real SEC fund filing does nothing to eliminate those medical-device risks.
TECHNOLOGY DEMONSTRATIONS SHOULD NOT BE CONFUSED WITH COMMERCIAL VALIDATION
PillBot is technically interesting. Endiatx describes it as a swallowable robotic capsule capable of real-time imaging and active physician-controlled navigation within the stomach. Its longer-term platform vision extends from diagnostic imaging toward biopsy, targeted intervention and microsurgery.
But much of that roadmap remains developmental.
For venture investors, the distinction between a working demonstration and a commercially scalable medical device is enormous. Endiatx still must navigate manufacturing reliability, clinical evidence, regulatory review, physician adoption, reimbursement, product liability, competition and unit economics.
The later-generation concepts—such as targeted robotic therapy or microsurgery—should be treated as future development ambitions rather than current commercial products.
This is not a criticism unique to Endiatx. It is the normal risk profile of frontier medtech. But because Series A-2 appears to provide concentrated exposure to exactly this kind of company, investors should price that uncertainty explicitly.
49 INVESTORS FILLED THE OFFERING ALMOST IMMEDIATELY
The fundraising itself is strong.
Series A-2 reports a September 30, 2026 first sale and a completely subscribed $13,359,060 offering by the time the Form D was filed on October 5. There are 49 investors and no reported non-accredited investors. Sales commissions and finder's fees are both reported as zero.
That level of demand is a positive market signal, but it does not establish investment quality.
A fully subscribed SPV can still be acquired at an aggressive valuation. Investors may also be investing primarily because they want access to a scarce private-company allocation. In those situations, access itself can command substantial economics.
The unusually large related-party payment makes that distinction important. Investors should determine exactly how much of each dollar subscribed ultimately purchases the underlying security.
THE $0 MINIMUM SHOULD NOT BE READ LITERALLY
Form D reports the minimum investment as $0. That should not be interpreted as meaning the fund accepted investments of any size.
The original PillBot fund is particularly useful for comparison. Although its Form D also reported a $0 minimum, Neman Ventures' later Form ADV disclosed a $10,000 minimum commitment for that fund.
This demonstrates why the Form D minimum field alone is not sufficient for understanding actual subscription economics.
Series A-2 investors should rely on the current subscription documents for minimum commitment requirements rather than interpreting "$0 reported on Form D" as an investment term.
WHAT WE WOULD VERIFY BEFORE INVESTING
The first question is the exact underlying security.
Investors should obtain proof that Series A-2 acquired the Endiatx security represented in the marketing materials, including the share class, price per share, financing-round valuation, liquidation preference, conversion terms, information rights and any restrictions attached to the SPV's shares.
Second, the full fee waterfall should be reconciled against the $1,935,359 related-person disclosure. Investors should know whether the $967,679.50 upfront payment is refundable under any circumstance, how the second five-year escrow is invested, who receives interest on escrowed cash, whether funds are released automatically, and what occurs after an early IPO, acquisition or secondary sale.
Third, Series A-2's own auditor, administrator, custodian and banking arrangements should be verified rather than inferred from the predecessor PillBot fund.
Finally, diligence on Endiatx should focus heavily on regulatory milestones. Investors should distinguish internal testing, clinical studies, FDA submissions and FDA clearance or approval. As of the company's current public disclosure, PillBot remains investigational and unavailable for commercial clinical use.
NEGATIVE CHECK: WHAT WE FOUND AND WHAT WE DID NOT FIND
The negative findings here are substantive but specific.
We found a $1.935 million related-party use-of-proceeds disclosure, representing approximately 14.5% of the total Series A-2 offering. We found a ten-year payment structure in which half is paid for the first five years and half is placed in escrow for years six through ten. We found a nearly identical long-duration structure in the predecessor PillBot SPV. And the underlying technology most clearly associated with the fund remains an investigational medical device without FDA clearance or approval.
At the same time, we did not find an SEC enforcement action naming NV PillBot Series A-2 Partners LLC in the sources reviewed. Neman Ventures is now an SEC-registered investment adviser, and its earlier PillBot fund appears in its Form ADV disclosures with an identified administrator, auditor and custodian.
The appropriate concern is therefore not "is this entity imaginary" The public record strongly suggests it is not.
The harder question is whether the net economics after related-party charges, the valuation paid for Endiatx exposure and the unresolved FDA/commercialization risk produce an attractive risk-adjusted investment.
FINAL ASSESSMENT
NV PillBot Series A-2 Partners LLC has one of the stronger verification chains among newly filed technology SPVs. Its $13.359 million Form D is fully subscribed, 49 investors are reported, Neman Ventures LLC is named as general partner, Neman Ventures is now an SEC-registered adviser, and an earlier PillBot vehicle is already documented in the adviser's Form ADV. There is also a credible public connection between Neman Ventures and Endiatx.
But stronger sponsor verification does not remove the economic risks.
Approximately $1.935 million—about 14.5% of the offering—is reported for payments to a related person, including a five-year upfront component and another five-year amount held in escrow. The predecessor PillBot fund used a similar structure. Meanwhile, PillBot remains an investigational device that has not received FDA clearance or approval and is not commercially available for clinical use.
Our conclusion is therefore verified sponsor, fully subscribed SPV and strong adviser trail, but unusually significant related-party economics layered on top of concentrated, pre-approval medical-device risk.
There is no verified evidence reviewed here establishing that NV PillBot Series A-2 Partners LLC is a scam. The more useful warning is narrower and stronger: investors should understand how much of their subscription actually buys Endiatx exposure, what Neman receives over the ten-year structure, and what happens to the investment if FDA authorization or commercialization takes materially longer than expected.